Skip Navigation
Skip to contents

KMJ : Kosin Medical Journal

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
3 "Procalcitonin"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original articles
Comparative analysis of Access PCT and Elecsys BRAHMS PCT assays for procalcitonin measurements
Hyunji Choi, Sang-Shin Lee, Hyunyong Hwang
Kosin Med J. 2024;39(4):272-280.   Published online December 20, 2024
DOI: https://doi.org/10.7180/kmj.24.155
  • 1,764 View
  • 61 Download
Abstract PDFPubReader   ePub   
Background
Procalcitonin (PCT) is a crucial biomarker for diagnosing sepsis and managing antibiotic therapy. This study evaluated the analytical performance and comparability of the Access PCT and Elecsys BRAHMS PCT assays.
Methods
The precision, detection capability, linearity, and reference range of both assays were assessed. A comparative analysis included 182 patient samples categorized into four risk groups to compare the results between Access PCT and Elecsys BRAHMS PCT assays.
Results
The Access PCT assay demonstrated precision within the manufacturer’s threshold, and its detection capabilities were verified. This assay exhibited excellent linearity and appropriate reference intervals. Comparative analysis indicated that the Access PCT assay reported higher overall PCT levels than the Elecsys BRAHMS assay, with high agreement between the assays (κ=0.941). However, the biases varied across different PCT concentration intervals.
Conclusions
Both the Access PCT and Elecsys BRAHMS PCT assays performed robustly with notable concordance but varying biases at different concentration intervals. The observed biases require careful consideration in clinical decision-making, especially when adopting novel assay systems. Standardizing the calibration across different platforms is recommended to improve assay comparability.
Prognostic Value of Procalcitonin in Pneumonia among Patients Admitted to Intensive Care Unit.
Deok Hee Kim, Hae Won Jung, Hyung Koo Kang
Kosin Med J. 2019;34(1):15-23.   Published online June 30, 2019
DOI: https://doi.org/10.7180/kmj.2019.34.1.15
  • 2,205 View
  • 30 Download
  • 1 Citations
Abstract PDFPubReader   ePub   
Objectives

Pneumonia is one of the leading causes of death in the intensive care unit (ICU). Many biomarkers for predicted prognosis have been suggested; among these, procalcitonin (PCT) is known to increase in cases of bacterial infection. However, there have been many debates regarding whether PCT is an appropriate prognostic marker for pneumonia. Therefore, we investigated whether PCT can serve as a biomarker for pneumonia, and compared it with CURB-65, which is a known tool for predicting the prognosis of pneumonia.

Methods

Levels of PCT and CURB-65 scores were compared between 30-day non-survival (n = 30) and survival (n = 101) patients. Relationships between PCT and CURB-65 were determined by using linear regression analysis, as well as by using receiver operating characteristic (ROC) curve analysis and calculation of the area under the curve (AUC). High and low PCT groups were compared.

Results

High PCT and high CURB-65 score were positively associated with 30-day mortality. For the prediction of 30-day mortality, initial PCT and CURB-65 exhibited AUCs of 0.63 and 0.66; these were not significantly different (P = 0.132). We found that the high PCT group had a higher rate of initial treatment failure (91%, P = 0.004).

Conclusions

Initial PCT can be a prognostic biomarker for mortality in severe pneumonia, similar to the CURB-65 score. Initial high PCT was positively associated with initial treatment failure.

Citations

Citations to this article as recorded by  
  • Pentraxin-3 as a novel biomarker in predicting outcomes of nosocomial pneumonia: a prospective observational study
    Isha Garg, Nishant Kumar Chauhan, Harsh Vardhan, Shrimanjunath Sankanagoudar, Naveen Dutt, Gopal Durgeshwar, Hariharan Iyer, Nikhil Kothari, Ravisekhar Gadepalli, Deepak Kumar
    Monaldi Archives for Chest Disease.2025;[Epub]     CrossRef
A study of the effectiveness of using the serum procalcitonin level as a predictive test for bacteremia in acute pyelonephritis
Ga Hee Lee, Yoo Jin Lee, Yang Wook Kim, Sihyung Park, Jinhan Park, Kang Min Park, Kyubok Jin, Bong Soo Park
Kosin Med J. 2018;33(3):337-346.   Published online December 31, 2018
DOI: https://doi.org/10.7180/kmj.2018.33.3.337
  • 2,328 View
  • 9 Download
Abstract PDFPubReader   
Objectives

Serum procalcitonin (PCT) is a specific biomarker that rises after bacterial infection, and levels of PCT are known to correlate with the severity and mortality of patients with pneumonia and sepsis. However, the usefulness of PCT levels in acute pyelonephritis is unknown. This study aimed to evaluate the effectiveness of using the PCT level as a predictive test for bacteremia in acute pyelonephritis.

Methods

Between January 2012 and June 2013, 140 patients diagnosed with acute pyelonephritis were admitted to Haeundae Paik Hospital. Serum PCT, C-reactive protein (CRP), and white blood cell (WBC) levels at pre- and post- treatment were measured. Blood and urine cultures were obtained from all patients. The levels of PCT, CRP, and WBCs were each compared between the blood culture-positive and blood culture-negative groups to assess their effectiveness in predicting bacteremia.

Results

Pre-treatment PCT level was 0.77 ng/mL (95% CI: 0.42–1.60 ng/mL) in the blood culture-negative group and 4.89 ng/mL (95% CI: 2.88–9.04 ng/mL) in the blood culture-positive group, and the increase between the two groups was statistically significant. The area under the receiver operating characteristic curve of PCT level for prediction of bacteremia was 0.728. A cut-off value of 1.23 ng/mL indicated a sensitivity of 79.0 % and specificity of 60.0 % for PCT level.

Conclusions

Serum PCT level is a useful predictive test for bacteremia in acute pyelonephritis. Through the early detection of bacteremia, serum PCT level can help estimate the prognosis and predict complications such as sepsis.


KMJ : Kosin Medical Journal
TOP